

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

VOLUNTARY ANNOUNCEMENT

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Huakang Biomedical Holdings Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business development of the Group.

The Board received a notification on 3 December 2021 from Smartac International Holdings Limited ("**Smartac**"), its issued shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 395), that its direct wholly-owned subsidiary, Forever Triumph Holdings Limited ("**Forever Triumph**") disposed (the "**Disposal**") 51% equity interests in Smartronic Limited ("**Smartronic**") to its independent third party (the "**New Smartronic Shareholder**"). The Group held 49% equity interests in Smartronic.

Nutronic Biomedical Group Limited (a wholly-owned subsidiary of the Company) ("**Nutronic Biomedical**") and the New Smartronic Shareholder entered into a new shareholders' agreement for the purpose of reaching agreement on a definitive and legally binding new distribution agreement for Smartronic, granting Smartronic a right to sell, market and distribute the healthcare products and supplements of "Nutronic" brand in the People's Republic of China and Hong Kong.

As at the date of this announcement, the ultimate beneficial owner of the New Smartronic Shareholder is one of the directors of Every Charming Inc., the Company's controlling shareholder (as defined in the Rules Governing the Listing of Securities on GEM of The Stock Exchange (the "**GEM Listing Rules**").

To the best knowledge, information and belief of the Board, having made all reasonable enquiries, save as disclosed above, the New Smartronic Shareholder and its ultimate beneficial owner are independent of and not connected with the Company and its connected persons (as defined in the GEM Listing Rules).

Shareholders and potential investors of the Company are urged to exercise caution when dealing in the shares of the Company.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 3 December 2021

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.